Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Edison Investment Research notes that despite macroeconomic uncertainty and heightened market volatility, BB Biotech’s portfolio companies continue to deliver on clinical and regulatory milestones. According to Edison, BB Biotech has responded proactively by consolidating its portfolio, increasing exposure to high-quality, larger-cap names, and enhancing risk management - positioning the investment company to capture long-term biotech growth at compelling valuations.

BB Biotech: staying the course amid market volatility

Edison Investment Research notes that despite macroeconomic uncertainty and heightened market volatility, BB Biotech’s portfolio companies continue to deliver on clinical and regulatory milestones. According to Edison, BB Biotech has responded proactively by consolidating its portfolio, increasing exposure to high-quality, larger-cap names, and enhancing risk management - positioning the investment company to capture long-term biotech growth at compelling valuations.
26.05.2025

This might also interest you

  • BB Biotech AG

    BB Biotech AG (SIX) (CHF)
    ISIN-No.: CH0038389992YTD: 23.47%Active share: 79.47Anzahl Positionen: 22
    Launch date: 16. November 1993